208
Views
19
CrossRef citations to date
0
Altmetric
Patent Evaluations

Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247)

, PhD
Pages 807-812 | Published online: 04 Apr 2011

Bibliography

  • Cuvillier O, Pirianov G, Kleuser B, Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800-3
  • Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 2006;39:113-31
  • Hait NC, Oskeritzian CA, Paugh SW, Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006;1758:2016-26
  • Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4:397-407
  • Sweeney EA, Sakakura C, Shirahama T, Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer 1996;66:358-66
  • Sakakura C, Sweeney EA, Shirahama T, Selectivity of sphingosine-induced apoptosis. Lack of activity of DL-erythyro-dihydrosphingosine. Biochem Biophys Res Commun 1998;246:827-30
  • Pitman MR, Pitson SM. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 2010;10:354-67
  • Wong L, Tan SS, Lam Y, Melendez AJ. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem 2009;52:3618-26
  • Paugh SW, Paugh BS, Rahmani M, A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 2008;112:1382-91
  • Mathews TP, Kennedy AJ, Kharel Y, Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem 2010;53:2766-78
  • French KJ, Zhuang Y, Maines LW, Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010;333:129-39
  • Hengst JA, Wang X, Sk UH, Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett 2010;20:7498-502
  • French KJ, Schrecengost RS, Lee BD, Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9
  • Foss FW Jr, Mathews TP, Kharel Y, Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs. Bioorg Med Chem 2009;17:6123-36
  • Maines LW, Fitzpatrick LR, Green CL, Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease. Inflammopharmacology 2010;18:73-85
  • Maines LW, Fitzpatrick LR, French KJ, Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 2008;53:997-1012
  • Maines LW, French KJ, Wolpert EB, Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci 2006;47:5022-31
  • De Luca T, Morre DM, Zhao H, Morre DJ. NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. Biofactors 2005;25:43-60
  • De Luca T, Bosneaga E, Morre DM, Morre DJ. Downstream targets of altered sphingolipid metabolism in response to inhibition of ENOX2 by phenoxodiol. Biofactors 2009;34:253-60
  • French KJ, Upson JJ, Keller SN, Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006;318:596-603
  • Rao BD, Buttlaire DH, Cohn M. 31P NMR studies of the arginine kinase reaction. Equilibrium constants and exchange rates at stoichiometric enzyme concentration. J Biol Chem 1976;251:6981-6
  • Onda M, Yoshihara K, Koyano H, Molecular recognition of nucleotides by the guanidinium unit at the surface of aqueous micelles and bilayers. A comparison of microscopic and macroscopic interfaces. J Am Chem Soc 1996;118:8524-30
  • Lynch KR, McDonalds TL, Mathews TP, Imidamide sphingosine kinase inhibitors. WO2011020116; 2011
  • Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.